REVA to Present at EuroPCR 2016

San Diego, California (Tuesday, May 10, 2016, PDT) – REVA Medical, Inc. (ASX: RVA) ("REVA" or the "Company") is pleased to announce the Company's scheduled presentations during the upcoming EuroPCR 2016 conference, which will be held May 17th through 20th in Paris, France.

REVA highlights include the release of six-month data on a majority of patients from Cohort A of the Company's FANTOM II clinical trial. The FANTOM II trial is evaluating the safety and performance of the *Fantom*® sirolimus-eluting bioresorbable scaffold in 240 patients. REVA is also presenting 12-month data from its FANTOM I pilot study and information about the Company's proprietary polymer, which is the foundation of the *Fantom* scaffold. The schedule of REVA's presentations is as follows:

Tuesday May 17, 2016
1:45 p.m. Session: First-in-Man and DES Trials
Room Maillot *Fantom Sirolimus-Eluting BRS*
Presented by Dr. A. Abizaid

Wednesday May 18, 2016
1:35 – 1:45 p.m. Symposium sponsored by REVA Medical
Room 342A *Advancing BRS through Innovative Biomaterials*
Presenters: Dr. N. Frey, Dr. L. Koltowski, Dr. G. Stone

Thursday May 19, 2016
5:48 p.m. Session: BRS, evolving technologies and applications
Room 351 *Results of the FANTOM I Trial*
Presented by Dr. J.D.R. Costa Jr.

The presentation materials delivered at the conference will be available in the Investor Relations section of REVA's website at *www.revamedical.com*.

About REVA

REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercialize its proprietary bioresorbable stents, which are called "scaffolds." The Company's scaffolds have been developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or "resorb") from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The

Company's initial product, the *Fantom*® scaffold, has been designed to offer an ideal balance of thinness and strength and distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require successful clinical trial results and regulatory approval before it can commercialize *Fantom* or any other product.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to obtain regulatory approvals, timely and successfully complete our clinical trials, protect our intellectual property position, commercialize our products if and when approved, develop and commercialize new products, recruit and retain our key personnel, and estimates regarding our capital requirements and financial performance. You should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the "SEC") on March 10, 2016, and as may be updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

United States
Investor & Media Enquiries:
REVA Medical, Inc.
Cheryl Liberatore
Director, Communications
+1 858-966-3045

Australia
Investor Enquiries:
Inteq Limited
Kim Jacobs
+61 438 217 279
Andrew Cohen
+61 408 333 452

Australia
Media Enquiries:
Buchan Consulting
Rebecca Wilson
+61 3 9866 4722